Xirui Xia
140 Jinye Avenue, Sanxi Community, Kuichong Subdistrict, Dapeng New District
Shenzhen, 518116, China
Shenzhen, 518116, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
In vivo PK/PD integration of p-furoylamphenmulin against Mycoplasma pneumoniae and its anti-inflammatory efficacy.
Journal: The Journal of antimicrobial chemotherapy
Published: January 15, 2026
Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative p-furoylamphenmulin against Mycoplasma gallisepticum in vivo in chickens.
Journal: Poultry science
Published: March 13, 2025
The novel pleuromutilin derivative 22-((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo.
Journal: Frontiers in pharmacology
Published: September 04, 2024
Pharmacokinetic/pharmacodynamic integration of amphenmulin: a novel pleuromutilin derivative against Mycoplasma gallisepticum.
Journal: Microbiology spectrum
Published: December 19, 2023
Emergence and Mechanism of Resistance of Tulathromycin Against Mycoplasma hyopneumoniae in a PK/PD Model and the Fitness Costs of 23S rRNA Mutants.
Journal: Frontiers in veterinary science
Published: November 20, 2021
The PK/PD Integration and Resistance of Tilmicosin against Mycoplasma hyopneumoniae.
Journal: Pathogens (Basel, Switzerland)
Published: May 10, 2020
Pharmacokinetic-pharmacodynamic integration and resistance of tiamulin against Mycoplasma hyopneumoniae in an in vitro dynamic model.
Journal: Microbial pathogenesis
Published: February 23, 2020
Pharmacokinetic and Pharmacodynamic Integration and Resistance Analysis of Tilmicosin Against Mycoplasma gallisepticum in an In Vitro Dynamic Model.
Journal: Frontiers in pharmacology
Published: March 22, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026